CN115551877A - 组合物和方法 - Google Patents

组合物和方法 Download PDF

Info

Publication number
CN115551877A
CN115551877A CN202180023593.1A CN202180023593A CN115551877A CN 115551877 A CN115551877 A CN 115551877A CN 202180023593 A CN202180023593 A CN 202180023593A CN 115551877 A CN115551877 A CN 115551877A
Authority
CN
China
Prior art keywords
binding protein
protein
composition
free light
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180023593.1A
Other languages
English (en)
Chinese (zh)
Inventor
R·邓恩
A·阿拉哈里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Haemalogix Pty Ltd
Original Assignee
Haemalogix Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020900948A external-priority patent/AU2020900948A0/en
Application filed by Haemalogix Pty Ltd filed Critical Haemalogix Pty Ltd
Publication of CN115551877A publication Critical patent/CN115551877A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/20—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the sorbent material
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Water Supply & Treatment (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
CN202180023593.1A 2020-03-27 2021-03-26 组合物和方法 Pending CN115551877A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2020900948 2020-03-27
AU2020900948A AU2020900948A0 (en) 2020-03-27 Composition and method
US202163200752P 2021-03-25 2021-03-25
US63/200,752 2021-03-25
PCT/IB2021/000171 WO2021191684A1 (en) 2020-03-27 2021-03-26 Composition and method

Publications (1)

Publication Number Publication Date
CN115551877A true CN115551877A (zh) 2022-12-30

Family

ID=77890984

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180023593.1A Pending CN115551877A (zh) 2020-03-27 2021-03-26 组合物和方法

Country Status (9)

Country Link
US (3) US20240262928A1 (https=)
EP (1) EP4126900A4 (https=)
JP (1) JP7817945B2 (https=)
KR (1) KR20230004543A (https=)
CN (1) CN115551877A (https=)
AU (1) AU2021244846A1 (https=)
BR (1) BR112022019076A2 (https=)
CA (1) CA3176109A1 (https=)
WO (1) WO2021191684A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025213238A1 (en) * 2024-04-12 2025-10-16 HaemaLogiX Ltd Anti-kma antibody formulations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR617901A0 (en) * 2001-07-06 2001-08-02 Pacmab Pty Ltd Method for treating multiple myeloma
US20120114555A1 (en) * 2009-04-07 2012-05-10 Immune System Therapeutics Ltd Method for treating immune disorders
ES2982297T3 (es) * 2009-12-18 2024-10-15 Novartis Ag Método de cromatografía de afinidad
WO2016031932A1 (ja) * 2014-08-27 2016-03-03 田辺三菱製薬株式会社 アルカリ洗浄によるＦｃ領域を有するタンパク質の製造方法
WO2016149088A1 (en) * 2015-03-13 2016-09-22 Bristol-Myers Squibb Company Use of alkaline washes during chromatography to remove impurities
BR112017022838A2 (en) * 2015-04-23 2018-07-17 Haemalogix Pty. Ltd kappa myeloma antigen chimeric antigen receptors and their uses
EP3492493A4 (en) * 2016-07-28 2020-03-18 Kaneka Corporation METHOD FOR PRODUCING AN ANTIBODY FRAGMENT
EP3774882A1 (en) * 2018-03-29 2021-02-17 Bristol-Myers Squibb Company Methods of purifying monomeric monoclonal antibodies

Also Published As

Publication number Publication date
KR20230004543A (ko) 2023-01-06
EP4126900A4 (en) 2024-05-29
AU2021244846A1 (en) 2022-11-24
JP2023518905A (ja) 2023-05-08
US20240262928A1 (en) 2024-08-08
BR112022019076A2 (pt) 2023-01-10
CA3176109A1 (en) 2021-09-30
WO2021191684A1 (en) 2021-09-30
US20240262925A1 (en) 2024-08-08
JP7817945B2 (ja) 2026-02-19
US20260035474A1 (en) 2026-02-05
EP4126900A1 (en) 2023-02-08

Similar Documents

Publication Publication Date Title
JP7744391B2 (ja) 抗ｖｅｇｆタンパク質組成物及びその製造方法
AU2014247034B2 (en) A method for increasing pyro-glutamic acid formation of a protein
CN107849087B (zh) 在亲和层析中减少宿主细胞蛋白的方法
HK1246330A1 (zh) 蛋白质纯化
CN112513097B (zh) 四价对称双特异性抗体
AU2018326458B2 (en) Method for purifying proteins
CN107849122B (zh) 用低电导率洗涤缓冲液进行亲和层析纯化
CN113583112B (zh) Aav特异性抗体及其应用
EP3060578A1 (en) Antibody purification
KR20250048376A (ko) 바이러스 오염물을 불활성화하는 방법
US20260035474A1 (en) Composition and method
AU2020221649B2 (en) Producing compositions comprising two or more antibodies.
WO2019224724A1 (en) Biopharmaceutical compositions comprising antibody variants
WO2020084503A1 (en) A composition comprising antibody with reduced level of basic variants thereof
CN114920842B (zh) 特异性结合pv-1蛋白的抗体或其抗原结合片段及其应用
WO2026067827A1 (zh) 一种制备异源多聚体的方法及应用
CN119874928A (zh) 基于免疫化学发光法的全能核酸酶残留检测试剂盒
HK1251584B (en) Method for the reduction of host cell proteins in affinity chromatography

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination